STOCK TITAN

Nanophase Reports Record Second Quarter Revenue and Profit

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Nanophase Technologies (OTCQB: NANX) reported record financial results for Q2 2024, with revenue reaching $13 million, a 10% increase from Q2 2023. The company's Solésence subsidiary saw a 44% year-over-year revenue increase to $11.2 million. Net income for Q2 was $856,000, a 157% increase from the same period last year.

For the first half of 2024, Nanophase reported revenue of $22.9 million, a 7% increase from H1 2023. Net income for H1 2024 was $1.7 million, compared to a net loss of $0.8 million in H1 2023. The company also won its third consecutive Cosmopack North America Formulation Award for its Lip Oil SPF 40+ product.

Nanophase Technologies (OTCQB: NANX) ha riportato risultati finanziari record per il secondo trimestre del 2024, con un fatturato che ha raggiunto 13 milioni di dollari, un aumento del 10% rispetto al secondo trimestre del 2023. La controllata Solésence della società ha registrato un aumento del fatturato del 44% anno su anno, raggiungendo 11,2 milioni di dollari. Il reddito netto per il secondo trimestre è stato di 856.000 dollari, un aumento del 157% rispetto allo stesso periodo dell'anno precedente.

Per il primo semestre del 2024, Nanophase ha riportato un fatturato di 22,9 milioni di dollari, un aumento del 7% rispetto al primo semestre del 2023. Il reddito netto per il primo semestre del 2024 è stato di 1,7 milioni di dollari, rispetto a una perdita netta di 0,8 milioni di dollari nel primo semestre del 2023. L'azienda ha anche vinto il terzo premio consecutivo Cosmopack North America Formulation Award per il suo prodotto Lip Oil SPF 40+.

Nanophase Technologies (OTCQB: NANX) reportó resultados financieros récord para el segundo trimestre de 2024, con ingresos que alcanzaron 13 millones de dólares, un aumento del 10% en comparación con el segundo trimestre de 2023. La subsidiaria Solésence de la compañía vio un aumento del 44% en los ingresos interanuales, alcanzando 11,2 millones de dólares. La ganancia neta para el segundo trimestre fue de 856,000 dólares, un aumento del 157% en comparación con el mismo periodo del año pasado.

Para la primera mitad de 2024, Nanophase reportó ingresos de 22,9 millones de dólares, un aumento del 7% en comparación con el primer semestre de 2023. La ganancia neta para la primera mitad de 2024 fue de 1,7 millones de dólares, en comparación con una pérdida neta de 0,8 millones de dólares en el primer semestre de 2023. La compañía también ganó su tercer premio consecutivo Cosmopack North America Formulation Award por su producto Lip Oil SPF 40+.

Nanophase Technologies (OTCQB: NANX)는 2024년 2분기에 기록적인 재무 결과를 보고하며, 매출이 1300만 달러에 달하여 2023년 2분기 대비 10% 증가했습니다. 회사의 자회사인 Solésence는 전년 대비 44%의 매출 증가를 보여주며 1120만 달러에 달했습니다. 2분기 순 이익은 856,000 달러로, 작년 같은 시기 대비 157% 증가했습니다.

2024년 상반기 동안 Nanophase는 2290만 달러의 매출을 기록하며, 2023년 상반기 대비 7% 증가했습니다. 2024년 상반기 순 이익은 170만 달러로, 2023년 상반기 80만 달러의 순손실에 비해 개선되었습니다. 이 회사는 또한 세 번째 연속 Cosmopack North America Formulation Award를 자신의 Lip Oil SPF 40+ 제품으로 수상했습니다.

Nanophase Technologies (OTCQB: NANX) a annoncé des résultats financiers records pour le deuxième trimestre 2024, avec un chiffre d'affaires atteignant 13 millions de dollars, soit une augmentation de 10% par rapport au deuxième trimestre 2023. La filiale Solésence de l'entreprise a connu une augmentation annuelle des revenus de 44%, atteignant 11,2 millions de dollars. Le revenu net pour le deuxième trimestre s'élevait à 856 000 dollars, une augmentation de 157% par rapport à la même période l'année dernière.

Pour le premier semestre 2024, Nanophase a réalisé un chiffre d'affaires de 22,9 millions de dollars, soit une augmentation de 7% par rapport au premier semestre 2023. Le revenu net pour le premier semestre 2024 était de 1,7 million de dollars, contre une perte nette de 0,8 million de dollars au premier semestre 2023. La société a également remporté son troisième Cosmopack North America Formulation Award consécutif pour son produit Lip Oil SPF 40+.

Nanophase Technologies (OTCQB: NANX) meldete rekordverdächtige finanzielle Ergebnisse für das zweite Quartal 2024, mit einem Umsatz von 13 Millionen Dollar, was einem Anstieg von 10% im Vergleich zum zweiten Quartal 2023 entspricht. Die Tochtergesellschaft Solésence des Unternehmens verzeichnete einen Umsatzanstieg von 44% im Jahresvergleich auf 11,2 Millionen Dollar. Der Nettogewinn für das zweite Quartal betrug 856.000 Dollar, was einem Anstieg von 157% im Vergleich zum Vorjahreszeitraum entspricht.

Für das erste Halbjahr 2024 berichtete Nanophase von einem Umsatz von 22,9 Millionen Dollar, was einem Anstieg von 7% im Vergleich zum ersten Halbjahr 2023 entspricht. Der Nettogewinn für das erste Halbjahr 2024 betrug 1,7 Millionen Dollar, im Vergleich zu einem Nettoverlust von 0,8 Millionen Dollar im ersten Halbjahr 2023. Das Unternehmen erhielt außerdem seinen dritten aufeinander folgenden Cosmopack North America Formulation Award für sein Lip Oil SPF 40+ Produkt.

Positive
  • Record Q2 revenue of $13 million, up 10% year-over-year
  • Solésence revenue increased 44% to $11.2 million in Q2
  • Q2 net income of $856,000, up 157% from Q2 2023
  • H1 2024 net income of $1.7 million, compared to $0.8 million loss in H1 2023
  • Third consecutive win at Cosmopack North America Formulation Award
  • Expecting second half revenue to exceed first half by more than 20%
  • Demonstrating margin performance above industry averages
Negative
  • None.

$13 Million in Q2 Revenue, with Solésence Revenue up 44% YOY 
$1.7 Million in Profitfor the First Half of 2024 alongside Record Q2 Profit 
—Record Third Win in a Row at Cosmoprof and Cosmopack North America 

ROMEOVILLE, Ill., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nanophase Technologies Corporation (OTCQB: NANX), a leader in mineral-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — today announced record financial results for the second quarter ended June 30, 2024.  

Jess Jankowski, President and Chief Executive Officer, commented: “The efforts we have made in the last half year are continuing to show results as we deliver another profitable quarter. We expect this progress to continue as we build the team needed to sustain our performance.” 

Kevin Cureton, Chief Operating Officer, commented: “We are now seeing that our company has the ability to simultaneously grow with our dynamic industry and improve our operational effectiveness. While the journey to becoming a best-in-class development and manufacturing organization has just begun, we are pleased with our progress. We were also both thrilled and humbled to make history this year at the Cosmoprof and Cosmopack North America Awards, when we took home our third consecutive Cosmopack North America Award for Formulation for our Lip Oil SPF 40+. Through the three years of Cosmopack Formulation Awards, we have demonstrated to our industry that SPF-infused beauty can be more aesthetically pleasing and outperform non-SPF products across categories, with a skincare product winning in 2022, a complexion product in 2023, and now a makeup product winning in 2024. The result is that consumers no longer have to choose between protecting their skin and looking their best – through the power of our technology and prowess of our teams, they can have it all!”  

Second Quarter Financial Highlights 

  • Revenue for the second quarter was $13 million, vs. $11.9 million for the same period in 2023, a 10% increase. 
    • Solésence revenue was $11.2 million, vs. $7.8 million for the same period in 2023, a 44% increase. 
  • Net income was $856,000 for the second quarter, vs. $333,000 for the same period in 2023, a 157% increase. 

Six-Month Financial Highlights 

  • Revenue for the six months ended June 30th was $22.9 million, vs. $21.3 million for the same period in 2023, a 7% increase. 
    • Solésence revenue was $19.3 million, vs. $12.8 million for the same period in 2023, a 51% increase. 
  • Gross profit for the six months ended June 30th was $7.3 million, vs $5.8 million for the same period in 2023, a 26% increase. 
  • Net income for the six months ended June 30th was $1.7 million, vs. a net loss of $0.8 million for the same period in 2023, a 312% increase. 
    • Net income as a percentage of sales was 8% for the period. 

Operational Highlights 

Solésence Beauty Science Won Third Consecutive Cosmopack North America Formulation Award  

Global Integration of KPIs 

  • In the second quarter, the Company implemented process improvements in the planning system to improve efficiencies and welcomed a new Operations Planning Manager to support ongoing growth in Production.  
  • In the first half of 2024, the Company integrated KPIs with global visibility across all departments and began the implementation of Overall Equipment Effectiveness (OEE) methodologies for evaluating performance and defining key opportunities for continued improvement.         

Jankowski continued: “With our second half revenue expected to exceed first half performance by more than 20%, we remain poised to continue the strong revenue growth that has been the hallmark of the past five years for our Company. We are now demonstrating margin performance above our industry averages enabled by our focus on both operational improvements and financial management to lower costs and contain expenses. We look forward to speaking with our investors about our record performance and sharing our positive outlook for the rest of 2024.”  

Conference Call 

Nanophase will host its Second Quarter Conference Call on Wednesday, August 7, 2024, at 11:00 a.m. CDT, 12:00 p.m. EDT, to discuss its financial results and provide a business and financial update. On the call will be Jess Jankowski, the Company’s President & CEO, joined by Kevin Cureton, the Company’s Chief Operating Officer.

Participant Registration: 

https://register.vevent.com/register/BI1f3051f859dd4b0e901722ef14e8ee82

To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call has begun. If you forget your PIN prior to the conference call, you can simply re-register. 

Listen-Only Webcast & Replay: 

https://edge.media-server.com/mmc/p/58zb87un

The call may also be accessed through the company’s website, at www.nanophase.com, by clicking on Investor Relations, Investor News, and the links in this conference call announcement release. Please connect to the conference at least five minutes before the call is scheduled to begin. 

FINANCIAL RESULTS AND NON-GAAP INFORMATION 

Use of Non-GAAP Financial Information 

Nanophase believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, Generally Accepted Accounting Principles (“GAAP”) and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with GAAP. 

About Nanophase Technologies 

Nanophase Technologies Corporation (OTCQB: NANX), www.nanophase.com, is a leading innovator in mineral-based and scientifically driven healthcare solutions across beauty and life science categories, as well as other legacy advanced materials applications. Leveraging a platform of integrated, patented and proprietary technologies, the Company creates products with unique performance, enhancing consumers' health and well-being. We deliver commercial quantity and quality engineered materials both as ingredients and as part of fully formulated products in a variety of formats.  

About Solésence Beauty Science 

Solésence, www.solesence.com, a wholly owned subsidiary of Nanophase Technologies, is changing the face of skin health with patented, mineral-based technology that is embraced by leading performance-driven and clean beauty brands alike. Our patented products for brands transform the way mineral actives look, feel and function — enabling textures never-before-seen in the mineral space and inclusivity never-before-seen in the sun care space. Solésence’s innovative formulations offer best-in-class UV protection, unparalleled free radical prevention to protect against pollution, and enhanced antioxidant performance. 

Forward-Looking Statements 

This press release contains words such as “expects,” “shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 28, 2024. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.  

Investor Relations Contact: 

Phone: (630) 771-6736 



  
NANOPHASE TECHNOLOGIES CORPORATION 
       
CONSOLIDATED BALANCE SHEETS 
(Unaudited Consolidated Condensed) 
   (in thousands except share and per share data) 
    
   June December 31, 
   2024
 2023
 
ASSETS(Unaudited)   
       
Current assets:    
 Cash$2,358  $1,722  
 Trade accounts receivable, less allowance for credit losses of $307    
  for June 30, 2024 and $225 for December 31, 2023 5,932   3,467  
 Inventories, net 13,874   10,031  
 Prepaid expenses and other current assets 2,096   1,082  
  Total current assets 24,260   16,302  
       
 Equipment and leasehold improvements, net 9,261   8,668  
 Operating leases, right of use 7,326   7,907  
 Other assets, net 2   4  
   $40,849  $32,881  
       
LIABILITIES AND STOCKHOLDERS' EQUITY    
Current liabilities:    
 Lines of credit - accounts receivable, related party 2,272   2,810  
 Current portion of long term debt, related party -   2,000  
 Current portion of operating lease obligations 1,043   1,297  
 Accounts payable 5,577   6,260  
 Current portion of deferred revenue 3,077   2,353  
 Accrued expenses 1,800   869  
  Total current liabilities 13,769   15,589  
       
 Long-term portion of operating lease obligations 8,714   9,152  
 Long-term debt - inventory, related party 5,200   5,000  
 Long-term debt, related party 1,000   1,000  
 Asset retirement obligation 242   238  
  Total long-term liabilities 15,156   15,390  
       
Shareholders' equity:    
 Preferred stock, $.01 par value, 24,088 shares authorized and    
  no shares issued and outstanding -   -  
 Common stock, $.01 par value, 95,000,000 and 60,000,000 shares authorized;    
  69,860,984 and 49,627,254 shares issued and outstanding on June 30, 2024    
  and December 31, 2023, respectively 698   496  
 Additional paid-in capital 114,140   106,069  
 Accumulated deficit (102,914)  (104,663) 
  Total stockholders' equity 11,924   1,902  
Total liabilities and shareholders' equity$40,849  $32,881  
       



  
NANOPHASE TECHNOLOGIES CORPORATION 
             
CONSOLIDATED STATEMENTS OF OPERATIONS 
(Unaudited Consolidated Condensed) 
             
(in thousands except share and per share data) 
             
     Three months ended Six months ended 
     June 30, June 30, 
      2024  2023  2024  2023  
Revenue:          
 Product revenue $12,923 $11,844 $22,694 $21,180  
 Other revenue  123  28  220  149  
  Net revenue  13,046  11,872  22,914  21,329  
             
 Cost of revenue  9,306  8,197  15,594  15,505  
  Gross profit  3,740  3,675  7,320  5,824  
             
Operating expense:         
 Research and development expense  864  991  1,776  1,994  
 Selling, general and administrative expense  1,829  2,105  3,388  4,255  
Income from operations  1,047  579  2,156  (425) 
 Interest expense  191  246  409  400  
 Other income, net  -  -  -  -  
Income before provision for income taxes  856  333  1,747  (825) 
Provision for income taxes  -  -  -  -  
Net income (loss) $856 $333 $1,747 $(825) 
             
             
Net income (loss) per share-basic $0.02 $0.01 $0.03 $(0.02) 
             
Weighted average number of common shares outstanding - basic  56,674,170  49,567,338  54,675,011  49,498,755  
             
Net income per share-diluted $0.01 $0.01 $0.03 $(0.02) 
             
Weighted average number of common shares outstanding - diluted  58,709,170  50,136,338  56,662,011  49,498,755  
             


             
NANOPHASE TECHNOLOGIES CORPORATION 
             
CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE 
(Unaudited Consolidated Condensed) 
             
(in thousands except share and per share data) 
             
     Three months ended Six months ended 
     June 30, June 30, 
     2024 2023 2024 2023
 
Revenue:          
 Product revenue $12,923 $11,844 $22,694 $21,180  
 Other revenue  123  28  220  149  
  Net revenue  13,046  11,872  22,914  21,329  
             
Operating expense:         
 Cost of revenue detail:         
 Depreciation  222  158  444  316  
 Non-Cash equity compensation  28  28  54  55  
 Other costs of revenue  9,056  8,011  15,096  15,134  
  Cost of revenue  9,306  8,197  15,594  15,505  
   Gross profit  3,740  3,675  7,320  5,824  
             
 Research and development expense detail:         
 Depreciation  5  7  11  14  
 Non-Cash equity compensation  32  45  65  92  
 Other research and development expense  827  939  1,700  1,888  
  Research and development expense  864  991  1,776  1,994  
             
 Selling, general and administrative expense detail:         
 Depreciation and amortization  7  8  14  15  
 Non-Cash equity compensation  97  123  198  258  
 Other selling, general and administrative expense  1,725  1,974  3,176  3,982  
  Selling, general and administrative expense  1,829  2,105  3,388  4,255  
Income from operations  1,047  579  2,156  (425) 
 Interest expense  191  246  409  400  
 Other income, net  -  -  -  -  
Income before provision for income taxes  856  333  1,747  (825) 
Provision for income taxes  -  -  -  -  
Net (loss) income $856 $333 $1,747 $(825) 
             
Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):         
 Addback Interest, net  191  246  409  116  
 Addback Depreciation/Amortization  234  134  469  269  
 Addback Non-Cash Equity Compensation  157  135  317  302  
 Subtract Non-Cash Other Income  -  -  -  -  
             
 Adjusted EBITDA $1,438 $848 $2,942 $(138) 
             



FAQ

What was Nanophase Technologies' (NANX) revenue for Q2 2024?

Nanophase Technologies (NANX) reported record Q2 2024 revenue of $13 million, a 10% increase from Q2 2023.

How much did Solésence's revenue grow in Q2 2024 compared to Q2 2023?

Solésence's revenue grew by 44% year-over-year, reaching $11.2 million in Q2 2024 compared to $7.8 million in Q2 2023.

What was Nanophase Technologies' (NANX) net income for the first half of 2024?

Nanophase Technologies (NANX) reported a net income of $1.7 million for the first half of 2024, compared to a net loss of $0.8 million in the same period of 2023.

What award did Solésence Beauty Science win at Cosmopack North America in 2024?

Solésence Beauty Science won the Formulation Award at Cosmopack North America for the third consecutive year in 2024 for its Lip Oil SPF 40+ product.

What is Nanophase Technologies' (NANX) revenue expectation for the second half of 2024?

Nanophase Technologies (NANX) expects second half revenue to exceed first half performance by more than 20% in 2024.

NANOPHASE TECHS CORP

OTC:NANX

NANX Rankings

NANX Latest News

NANX Stock Data

139.20M
17.67M
75.23%
0.97%
0.49%
Specialty Chemicals
Basic Materials
Link
United States of America
Romeoville